Last reviewed · How we verify

NCT06242730: DOXY-MEN

Doxycycline PEP and 4CMenB as a Comprehensive Prevention Strategy in MSM and TGW at High Risk for Bacterial STIs Within the Swiss HIV Cohort Study

Status unknown Last updated 5 February 2024
What this trial tests

trial in Doxycycline STI PEP in 400 participants. Status unknown.

Timeline
1 November 2023
Primary endpoint
31 October 2024
31 October 2025

Quick facts

Lead sponsorUniversity of Zurich
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment400
Start date1 November 2023
Primary completion31 October 2024
Estimated completion31 October 2025
Sites1 location across Switzerland

Conditions studied

Sponsor

University of Zurich

Who can join

18 and older, any sex, with Doxycycline STI PEP. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims at assessing effectiveness of offering event-driven Doxy PEP and 4CMenB immunization in MSM/TGW at high STI risk. It plans to offer this STI prevention package to all MSM/TGW in the SHCS who are at risk of STI and then comparing 12-months STI incidence between those accepting and those not accepting the prevention package. The proposal further hosts two interesting sub-studies: One assessing potential effect of Doxy PEP on the microbiome and the other one assessing potential impact of Doxy PEP on TP, MG and CT resistance.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Zurich trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06242730.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing